Controversies, Confusion, and the Future of Urologic Post-Operative Opioid Prescribing Reduction Strategies (2022)
This activity includes a multidisciplinary panel of experts discussing how urologists can reduce opioid prescribing, non-opioid multi-modal options, alternative therapies to pain management, managing opioid tolerant patients, and upcoming post-operative pain management opportunities.
- Advanced Practice Providers
After participating in this activity, learners will be able to:
- Identify at least one non-pharmaceutical method they can practically implement to manage post-operative pain and reduce post-operative opioid prescribing.
- Discuss multi-modal pain control and identify at least two non-opioid medications which can be used to manage post-operative pain and reduce post-operative opioid prescribing.
- Panelist Introduction and CME Housekeeping
- Introduction to White Paper
- What is the ONE easy thing any Urologist can do to safely reduce their opioid prescribing?
- Non-Opioid Multi-Modal Options: Practical Details & Controversies
- Helpful or Harmful?
- Managing Opioid Tolerant Patients beyond Consulting Pain Specialists
- What’s coming on the horizon for post-op pain management that excites you?
- Wrap Up
QUALITY IMPROVEMENT & PATIENT SAFETY COMMITTEE
COI REVIEW WORK GROUP
|Name||Company Name||Relationship Type||End Date|
|Abraham, Nitya E.||Urovant||Meeting Participant or Lecturer||10/27/2021|
|Brummett, Chad||Heron Therapeutics||Intellectual Property||Current|
|Brummett, Chad||Peripheral Perineural Dexmedetomidine||Intellectual Property||Current|
|Auffenberg, Gregory||No relevant financial relationships|
|Robles, Jennifer||No relevant financial relationships|
|Sternberg, Kevan||No relevant financial relationships|
AUA Staff have no relevant financial relationships.
All relevant financial relationships have been mitigated.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by watching the webcast, viewing the resources and references provided and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest (aka ineligible company) during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
MITIGATION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:
- Peer review for valid, evidence-based content by the AUA COI Review Work Group.
- Attestation that clinical recommendations are evidence-based and free of commercial bias.
- Introduction of a debate format (point-counterpoint)
- Inclusion of moderated panel discussion with unbiased moderator
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Divestiture of the relationship by faculty
- Recusal from controlling relevant aspects of planning
- Selection of alternative faculty for specific topic
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 0.75 AMA PRA Category 1 Credit™
- 0.75 Non-Physician Participation